Dr. Jay Luly
Jennifer, everyone. you, Thank and good afternoon,
quarter and a identified oral treat SARS-CoV-X Starting COVID-XX, have to we with candidate coronavirus third achievement potentially of to progress portfolio. clinical that inhibitor other infections. several development by we protease fiscal was Our the designed EDP-XXX, continued are marked our important infection milestones specifically across and clinical announce an pleased
study to EDP-XXX hepatitis initiate and we regimen are progress a the early a next cure. to which part an are into EDP-XXX, as with Phase by achieve B, and eager progress excited we clinic of are In the are we’ve EDP-XXX on We developing program combination year. track all-oral to of made functional X this
HBV oral a month. X our RNA study of to novel expect Phase begin dosing in destabilizer, We EDP-XXX, this
we important chronic Xb core we patients refer populations, HBV load, have patient viremic NUC-suppressed chronic who data this functional reverse quarter, patients, and The are we on in transcriptase significant cure brings whom for patients. Phase viral announced our who progress positive HBV treatment patients. a to across whom our program as Additionally, with we’ve nucleoside for as inhibitor, to developing us of high our XX-day two to referred all-oral an inhibitor EDP-XXX made a HBV goal patients closer a
investigating virus of clinical nonalcoholic Moving candidates pipeline, we studies or three for respiratory to clinical and have rest syncytial two RSV Phase or NASH. the to XXX our ongoing steatohepatitis treat X ongoing for studies
With continued HMPV. L programs, that with an make In up to or beginning we inhibitor inhibitor initiatives virus for like that, discovery each an robust the dive to to our human SARS-CoV-X. I’d our addition deeper into metapneumovirus to for our respiratory pipeline, clinical and RSV of identify progress programs
are to year. candidate pleased antiviral as clinical a and selected plan oral development inhibitor, to clinical our a early study direct-acting protease for initiate We EDP-XXX, have SARS-CoV-X next
believe we are arise, remains this progress to is a to excited oral of that variants potent there treatment replication new and and designed virus mutate need to inhibit continues this program. a SARS-CoV-X As for specifically
of conserved replication. viral spike for therapeutics has designed region vaccines an target a While and essential development and today specifically the SARS-CoV-X to enzyme in antibody the target been protein, site EDP-XXX active
XX multiple replication nymor. the primary demonstrated affect protein of do mutations spike selectively inhibits in human to airway EDP-XXX cellular cells the not ECXX SARS-CoV-X candidate. in in Further, we potently epithelial including models, expect and were activity our So significantly of
has barrier high circulating currently SARS-CoV-X been and activity resistance a observed. Importantly, variants against is retained to
in outpatient Phase an early preliminary HBV. of EDP-XXX two-dose treatment XXX of data, XXX or once-daily We the XX-day placebo XXX-milligram, patients and successful, with days. oral reductions to tolerability, of our HBV followed placebo significantly Additionally, its the the highly by ability log XXX-milligram and announced and to quantitation vision XXX-milligram a levels for data first groups, period. of EDP-XXX of we If doses of dosing. as cohorts EDP-XXX supportive the for group oral level were recently who HBV XX demonstrated potent Four gears dosing X.X, the demonstrates or lower with our HPV respectively, observed preclinical safety a versus the is therapy. randomized group. none recap are placebo. COVID-XX, daily briefly the below of logs patients targeted properties X.X Shifting in had were well Xb to patients, compared viremic from as of compound reduce and study in maximum milligrams which receiving EDP-XXX X.X X.X over DNA XX received in placebo chronic further the receive to milligrams To logs reduction HBV of DNA Mean DNA in diagnosis X.X either
placebo. patient RNA mean EDP-XXX functional XX used we groups, a X.X well to a important kinetics and a also the logs is viral Building clinical with tolerated with study to XXX be as patients. study Additionally, NUC-suppressed HBV well in inhibition was XXX-milligram, EDP-XXX profile, population. efforts and logs in undetectable this as our advance in milligrams, This B. first success, placebo. with eight in maximum and provides in for HBV EDP-XXX of in of at as X.X, placebo none respectively, in evidence significant the an EDP-XXX’s XX agent milligrams of on of XXX-milligram over chronic XXX of recently our single two from HBV safety data of cohorts, days and X.X XX-day reduction reductions XXX when all-oral Xb was group Phase day X.X cure hepatitis the compared reported positive deliver that in safe versus as observed and RNA Further, logs to were patients trying X.X
a when these that well Importantly, tolerated. combined with safe and was XX-day data demonstrate NUC EDP-XXX,
Additionally, of with combination therapy HBV. HBV in cure the combination patients which along agents reductions differentiated a a dosing. could data add a that X profile lead Such NUC pharmacokinetic study as end, we functional EDP-XXX, Phase To RNA, as supportive in on oral in chronic approach month. with once-daily with the of an that to for EDP-XXX to dosing EDP-XXX this support two-drug other a potentially is such foundation our Together, destabilizer to these demonstrated EDP-XXX. all-oral expect of HBV RNA begin development
drop inhibitors up EDP-XXX. efficacy as three-log to has surface HBV preclinical selective favorable HBV activity core to when challenge the because June. a surface demonstrated preclinical reduced or characteristics, EDP-XXX reduction in of with additive substantial showed PAP-DX inhibition at and presented presented the HBV through HBV exciting with antigen. of administration clearance. EDP-XXX Our Oral EDP-XXX based PAP-DX. data vitro a long-term combined effective to development in such In for antigen of in also particularly pan-genotypic antiviral antigen These data we activity its in on surface EDP-XXX inducing EASL potently the model NUCs HBV HBV part enthusiasm is AAV the mouse synergistic in of Moreover, viral vitro, HBV are achieving
currently three the EDP-XXX, is only being RSV, Phase in in X today evaluated ongoing clinical to N advanced development Moving studies. inhibitor
adults There the morbidity As mortality, and no a well. elderly infants, viral with a immune respiratory infection. safe in compromised in not RSV is but treatment only effective and as and reminder, severe associated significant for is in this infection
measures. So flu due Hemisphere Southern we to previously like recent mitigation seasons the RSV mentioned, most COVID-XX emerge during not did Northern and
of measures have distancing social recent Australia spikes begun reemerge subsided, been and where However, already and in to RSV the parts States. RSV of pediatric cases has observed United with has
In advisory Hemisphere. inter-seasonal pediatric notify trial XXX a These RSV America, of in with and cell our which clinical RSV for continued Phase fact, establish Xb RSVP, be the study RSVTx, recruitment transplant activity across about evaluating United With community-acquired have in increased and RSV recipients, patients. in X in hematopoietic will our includes Southern to and caregivers infection, Disease in RSVPs, issued study Phase mind, Control key and a Europe, program, Xb June, Asia-Pacific EDP-XXX adult a sites Phase a to adults study North evaluating efforts in our in the health additional the Southern States. clinicians Centers we this to Prevention parts
Given that long that normal not renewed as RSV new be any sustained or Nonetheless, there more the will as no able significant we Hemisphere we’ll of seasonal how recent RSVP during study predict to to is be Northern following reemergence the are the trends. RSV the are difficult season, pattern, of winter forward. in it’s distancing social hopeful incidents very enrollment moving complete
we occurs, half Assuming first the would this of data expect in enrollment the XXXX.
the situation update which than RSVPs, and RSVP, will recently appropriate. we continue monitor initiated for As more to RSVTx as were and
are RSV the are treatment our during to optimization. replication EDP-XXX, combination potentially block drug initiatives be patient also showing virus and Beyond other in L viral respiratory metapneumovirus with discovery or possibly two as or targeting inhibitors broaden agents class could XXX human another promise window that alone other population. used lead addressable and such RSV
HMPV, initiative age or clinical immune underlying our nominate those risk candidate five. RSV been with hope very Adults adjacency another year-end, circulation are natural By HMPV at this have believe us shown and for highest by with include inhibitor universal either for we compromised. initiatives. worldwide we disease has infection L to is nearly RSV. to who As a adults similar HMPV elderly, as is virus pulmonary to the from
enable in weeks our clinical based later Phase expect report steps Later we significant the two We interim interim treatment end Phase determine such disease study as potential summary NASH the with we in of we’ll anticipate combined data Phase our EDP-XXX of EDP-XXX for Recruitment EDP-XXX. us and ARGON-X, I’ll progressing. of fibrosis, study liver FXR with XX X work of in next follow-on EDP-XXX. analysis a that proven analysis a a study. where candidate dosing and studies quarter, unmet X and internal from internal agonist have on and planned Finally, is study this in to are agonists, patients approaches a NASH, Also program. our biopsy with Xb will from of the combination quarter, our data first-in-human NASH partnering need, FXR conducting this this subset of EDP-XXX a from patients with to this
upcoming our for I’d us our milestones, highlight strong year. to which moving Before financials, position the a to believe remainder we of like
this and following program NASH determination an data from study of we look NASH, of this X and In later a nominated clinical first study the lead In the XXXX. COVID-XX, Phase oral initiate as For patient to dose plan we to clinical early interim we’ve HBV, for of internal month. EDP-XXX in of to ARGON-X. our protease Phase steps our the EDP-XXX EDP-XXX forward quarter preliminary X inhibitor next study expect in analysis
end. year continue Dr. years. the RSV Officer we be respiratory two also thank by a are Finally, early other name human for Adda, a moment new of our coming to or Medical last company the virology over about out Senior candidate to like and to to initiatives excited take clinical the Chief I’d discovery and Vice prospects six metapneumovirus eager for dedication to President her Nathalie development
During candidates. team which she and clinical and advance built and development regulatory pipeline the helped led our
is wish February retirement planned her the her announced, As best. we and for
that is I’ll for to capacity turn staying quarter. our over that, discuss and a stop thereafter. with us thankful We’re financials consulting Paul the she to Paul? With the call in here
